Introduction
Methods
Patients
Blood sampling and platelet function testing
Study outcome measures and definitions
Follow-up
Statistical methods
Results
Patients
Characteristic | AA-induced platelet aggregation | P value | |
---|---|---|---|
With HAPR (n = 952) | Without HAPR (n = 3887) | ||
Age (years) | 68.5 ± 11.1 | 67.8 ± 10.8 | 0.07 |
Women | 201 (21.1) | 929 (23.9) | 0.07 |
Diabetes mellitus | 268 (28.2) | 1124 (28.9) | 0.64 |
On insulin therapy | 89 (9.3) | 347 (8.9) | 0.68 |
Arterial hypertension | 372 (39.1) | 1821 (46.8) | < 0.001 |
Hypercholesterolemia | 636 (66.8) | 2855 (73.4) | < 0.001 |
Active smoker | 139 (14.6) | 665 (17.1) | 0.06 |
Body mass index (kg/m2) | 27.1 ± 4.2 | 27.7 ± 4.4 | 0.002 |
Left ventricular ejection fraction | 52.6 ± 12.2 | 53.6 ± 11.2 | 0.11 |
Serum creatinine (mg/dl) | 1.1 ± 0.4 | 1.1 ± 0.7 | 0.10 |
GFR (ml /min) | 84.2 ± 34.3 | 88.5 ± 35.4 | < 0.001 |
C-reactive protein (mg/L) | 13.7 ± 35.4 | 8.1 ± 22.8 | 0.001 |
ADP-induced platelet aggregation (AU x min) | 367.5 ± 272.7 | 259.6 ± 223.1 | < 0.001 |
Previous myocardial infarction | 256 (26.9) | 1020 (26.2) | 0.68 |
Previous bypass surgery | 138 (14.5) | 566 (14.6) | 0.96 |
Coronary artery disease | 0.67 | ||
1-vessel disease | 163 (17.1) | 619 (15.9) | |
2-vessel disease | 253 (26.6) | 1043 (26.8) | |
3-vessel disease | 536 (56.3) | 2225 (57.2) | |
Number of lesions | 1.8 ± 1.0 | 1.8 ± 0.9 | 0.98 |
Clinical presentation | 0.05 | ||
ST-segment elevation MI | 104 (10.9) | 367 (9.4) | |
Non-ST-segment elevation MI | 50 (5.3) | 149 (3.8) | |
Unstable angina | 234 (24.6) | 1072 (27.6) | |
Stable angina | 564 (59.2) | 2299 (59.2) |
Characteristic | AA-induced platelet aggregation | P value | |
---|---|---|---|
With HAPR (1695 lesions) | Without HAPR (6814 lesions) | ||
Left main coronary artery | 86 (5.1) | 353 (5.2) | |
Left anterior descending coronary artery | 692 (40.8) | 2702 (39.7) | |
Left circumflex coronary artery | 422 (24.9) | 1711 (25.1) | |
Right coronary artery | 466 (27.5) | 1898 (27.9) | |
Venous bypass graft | 29 (1.7) | 150 (2.2) | |
Complex (type B2 or C) lesions | 1242 (73.3) | 5058 (74.2) | 0.42 |
Chronic occlusions | 96 (5.7) | 371 (5.4) | 0.72 |
Ostial lesions | 392 (23.1) | 1610 (23.6) | 0.66 |
Bifurcation lesions | 494 (29.1) | 2022 (29.7) | 0.67 |
Type of intervention | 0.02 | ||
Placement of drug-eluting stent | 1626 (95.9) | 6497 (95.4) | |
Placement of bare-metal stent | 23 (1.4) | 58 (0.9) | |
Balloon angioplasty | 46 (2.7) | 259 (3.8) | |
Lesion length (mm) | 16.0 ± 9.7 | 16.2 ± 25.5 | 0.88 |
Reference diameter (mm) | 2.8 ± 0.6 | 2.9 ± 0.6 | 0.04 |
Primary endpoint (clinical restenosis)
Secondary endpoints (angiographic outcomes)
Characteristic | AA-induced platelet aggregation | P value | |
---|---|---|---|
With HAPR (1085 lesions) | Without HAPR (5216 lesions) | ||
Binary restenosis (%) | 165 (15.2) | 777 (14.9) | 0.79 |
Late lumen loss (mm) | 0.32 ± 0.57 | 0.32 ± 0.59 | 0.93 |
Late lumen loss (mm)a | 0.18 [− 0.04 to 0.50] | 0.17 [− 0.04 to 0.49] | 0.46 |
Diameter stenosis (%) | 32.8 ± 18.4 | 32.8 ± 18.6 | 0.92 |
Minimal lumen diameter (mm) | 1.99 ± 0.69 | 2.01 ± 0.71 | 0.54 |